TW200634026A - Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy - Google Patents
Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapyInfo
- Publication number
- TW200634026A TW200634026A TW094144950A TW94144950A TW200634026A TW 200634026 A TW200634026 A TW 200634026A TW 094144950 A TW094144950 A TW 094144950A TW 94144950 A TW94144950 A TW 94144950A TW 200634026 A TW200634026 A TW 200634026A
- Authority
- TW
- Taiwan
- Prior art keywords
- therapy
- autoimmune disease
- patients
- failed prior
- antiangiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63716904P | 2004-12-17 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200634026A true TW200634026A (en) | 2006-10-01 |
Family
ID=36177836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094144950A TW200634026A (en) | 2004-12-17 | 2005-12-16 | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060134111A1 (zh) |
EP (1) | EP1824885A1 (zh) |
JP (1) | JP2008524241A (zh) |
KR (1) | KR20070086218A (zh) |
CN (1) | CN101120020A (zh) |
AR (1) | AR052056A1 (zh) |
AU (1) | AU2005316403A1 (zh) |
BR (1) | BRPI0518105A (zh) |
CA (1) | CA2587932A1 (zh) |
CR (1) | CR9181A (zh) |
IL (1) | IL183347A0 (zh) |
MA (1) | MA29366B1 (zh) |
MX (1) | MX2007007165A (zh) |
NO (1) | NO20073651L (zh) |
NZ (1) | NZ555286A (zh) |
PE (1) | PE20061075A1 (zh) |
RU (1) | RU2007126970A (zh) |
SG (1) | SG158089A1 (zh) |
SV (1) | SV2006002342A (zh) |
TN (1) | TNSN07191A1 (zh) |
TW (1) | TW200634026A (zh) |
WO (1) | WO2006066086A1 (zh) |
ZA (1) | ZA200704898B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0201009A2 (en) * | 1999-05-07 | 2002-07-29 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
KR20040023565A (ko) * | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
EP1804835B9 (en) * | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Multimeric constructs |
GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010054221A2 (en) * | 2008-11-06 | 2010-05-14 | The Johns Hopkins University | Treatment of chronic inflammatory respiratory disorders |
EP4169951A1 (en) * | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
AU2009331955B2 (en) * | 2008-12-23 | 2015-09-24 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | VEGF antagonist compositions and their use |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
MX2016012779A (es) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
EP3056216B1 (en) * | 2015-02-11 | 2017-02-01 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with bevacizumab |
KR20200130403A (ko) | 2018-03-09 | 2020-11-18 | 아게누스 인코포레이티드 | 항-cd73 항체 및 그의 사용 방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
JP4926320B2 (ja) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2005
- 2005-12-16 KR KR1020077013483A patent/KR20070086218A/ko not_active Application Discontinuation
- 2005-12-16 WO PCT/US2005/045600 patent/WO2006066086A1/en active Application Filing
- 2005-12-16 AU AU2005316403A patent/AU2005316403A1/en not_active Abandoned
- 2005-12-16 PE PE2005001499A patent/PE20061075A1/es not_active Application Discontinuation
- 2005-12-16 RU RU2007126970/15A patent/RU2007126970A/ru not_active Application Discontinuation
- 2005-12-16 SG SG200907898-1A patent/SG158089A1/en unknown
- 2005-12-16 EP EP05854343A patent/EP1824885A1/en not_active Withdrawn
- 2005-12-16 US US11/303,811 patent/US20060134111A1/en not_active Abandoned
- 2005-12-16 MX MX2007007165A patent/MX2007007165A/es not_active Application Discontinuation
- 2005-12-16 AR ARP050105315A patent/AR052056A1/es not_active Application Discontinuation
- 2005-12-16 SV SV2005002342A patent/SV2006002342A/es unknown
- 2005-12-16 TW TW094144950A patent/TW200634026A/zh unknown
- 2005-12-16 CA CA002587932A patent/CA2587932A1/en not_active Abandoned
- 2005-12-16 ZA ZA200704898A patent/ZA200704898B/xx unknown
- 2005-12-16 JP JP2007546933A patent/JP2008524241A/ja not_active Withdrawn
- 2005-12-16 BR BRPI0518105-4A patent/BRPI0518105A/pt not_active IP Right Cessation
- 2005-12-16 NZ NZ555286A patent/NZ555286A/en not_active IP Right Cessation
- 2005-12-16 CN CNA2005800481049A patent/CN101120020A/zh active Pending
-
2007
- 2007-05-18 TN TNP2007000191A patent/TNSN07191A1/fr unknown
- 2007-05-21 IL IL183347A patent/IL183347A0/en unknown
- 2007-06-13 CR CR9181A patent/CR9181A/es not_active Application Discontinuation
- 2007-07-12 MA MA30069A patent/MA29366B1/fr unknown
- 2007-07-16 NO NO20073651A patent/NO20073651L/no not_active Application Discontinuation
-
2008
- 2008-02-19 US US12/033,557 patent/US20080214789A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CR9181A (es) | 2008-07-31 |
PE20061075A1 (es) | 2006-11-15 |
MX2007007165A (es) | 2007-08-14 |
RU2007126970A (ru) | 2009-01-27 |
SV2006002342A (es) | 2006-06-01 |
US20060134111A1 (en) | 2006-06-22 |
JP2008524241A (ja) | 2008-07-10 |
IL183347A0 (en) | 2007-09-20 |
MA29366B1 (fr) | 2008-04-01 |
TNSN07191A1 (en) | 2008-11-21 |
NO20073651L (no) | 2007-09-10 |
CA2587932A1 (en) | 2006-06-22 |
US20080214789A1 (en) | 2008-09-04 |
NZ555286A (en) | 2010-04-30 |
ZA200704898B (en) | 2009-03-25 |
KR20070086218A (ko) | 2007-08-27 |
CN101120020A (zh) | 2008-02-06 |
WO2006066086A1 (en) | 2006-06-22 |
BRPI0518105A (pt) | 2008-11-04 |
AU2005316403A1 (en) | 2006-06-22 |
EP1824885A1 (en) | 2007-08-29 |
AR052056A1 (es) | 2007-02-28 |
SG158089A1 (en) | 2010-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG158089A1 (en) | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy | |
WO2007136518A3 (en) | Treatment of autoimmune disorders | |
CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
TW200640488A (en) | Extending time to disease progression or survival in cancer patients | |
WO2008150490A3 (en) | Uses and compositions for treatment of psoriasis and crohn's disease | |
RS20150135A1 (en) | TREATMENT WITH ANTI-VEGF ANTIBODIES | |
EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
TNSN07376A1 (en) | Npy antagonists, preparation and use | |
EA201170149A1 (ru) | Новые аналоги инсулина пролонгированной активности | |
BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2006029142A3 (en) | Methods and systems for treating asthma and other respiratory diseases | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
WO2003039539A3 (de) | Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen | |
WO2009033819A3 (en) | Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids | |
PT1670489E (pt) | Utilização de xénon com hipotermia para o tratamento de asfixia neonatal | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
IL174134A0 (en) | Use of a protein in the preparation of a medicament for treatment of fibrotic diseases | |
MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. |